Synonyms: Aklief® | CD5789 | compound 15b [PMID: 29706423]
trifarotene is an approved drug (FDA (2019))
Compound class:
Synthetic organic
Comment: Trifarotene (CD5789) is a RARγ-selective agonist that was developed as a topical anti-acne therapeutic [1-2,4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Aubert J, Piwnica D, Bertino B, Blanchet-Réthoré S, Carlavan I, Déret S, Dreno B, Gamboa B, Jomard A, Luzy AP et al.. (2018)
Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol, 179 (2): 442-456. [PMID:29974453] |
2. Balak DMW. (2018)
Topical trifarotene: a new retinoid. Br J Dermatol, 179 (2): 231-232. [PMID:30141539] |
3. Blume-Peytavi U, Fowler J, Kemény L, Draelos Z, Cook-Bolden F, Dirschka T, Eichenfield L, Graeber M, Ahmad F, Alió Saenz A et al.. (2020)
Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol, 34 (1): 166-173. [PMID:31306527] |
4. Thoreau E, Arlabosse JM, Bouix-Peter C, Chambon S, Chantalat L, Daver S, Dumais L, Duvert G, Feret A, Ouvry G et al.. (2018)
Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. Bioorg Med Chem Lett, 28 (10): 1736-1741. [PMID:29706423] |